Skip to Content

Hycamtin Dosage

Generic name: TOPOTECAN HYDROCHLORIDE 4mg in 4mL
Dosage form: injection, powder, lyophilized, for solution

Medically reviewed on September 5, 2018.

Important Safety Information

Verify dosage using body surface area. Do not exceed a single dose of 4 mg intravenously.

Recommended Dosage for Ovarian Cancer

The recommended dosage of HYCAMTIN for injection is 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity.

Recommended Dosage for Small Cell Lung Cancer (SCLC)

The recommended dosage of HYCAMTIN for injection is 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle.

Recommended Dosage for Cervical Cancer

The recommended dosage of HYCAMTIN for injection is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on Days 1, 2, and 3, in combination with cisplatin 50 mg/m2 on Day 1, of a 21-day cycle.

Dose Modifications for Adverse Reactions

Hematologic

Do not administer subsequent cycles of HYCAMTIN for injection until neutrophils recover to greater than 1,000/mm3, platelets recover to greater than 100,000/mm3, and hemoglobin levels recover to greater than or equal to 9 g/dL (with transfusion if necessary).

For HYCAMTIN for injection as a single agent, reduce the dose to 1.25 mg/m2/day for:

  • neutrophil counts of less than 500/mm3 or administer granulocyte-colony stimulating factor (G-CSF) starting no sooner than 24 hours following the last dose
  • platelet counts less than 25,000/mm3 during previous cycle

For HYCAMTIN for injection in combination with cisplatin, reduce the dose to 0.6 mg/m2/day (and further to 0.45 mg/m2 if necessary) for:

  • febrile neutropenia (defined as neutrophil counts less than 1,000/mm3 with temperature of greater than or equal to 38.0°C (100.4°F) or administer G-CSF starting no sooner than 24 hours following the last dose
  • platelet counts less than 25,000/mm3 during previous cycle

Dosage Modification for Renal Impairment

For HYCAMTIN for injection as a single agent, reduce the dose to 0.75 mg/m2/day for patients with creatinine clearance (CLcr) of 20 to 39 mL/min (calculated with the Cockcroft-Gault method using ideal body weight) [see Clinical Pharmacology (12.3)].

Preparation and Intravenous Administration

  • Visually inspect for particulate matter and discoloration prior to administration, whenever solution and container permit.

Preparation

  • Reconstitute each 4 mg vial of HYCAMTIN for injection with 4 mL Sterile Water for Injection, USP.
  • Dilute the appropriate volume of the reconstituted solution in either 0.9% Sodium Chloride Intravenous Infusion, USP or 5% Dextrose in Water Injection, USP.

Stability

  • Because the vials contain no preservative, use contents immediately after reconstitution. Discard any unused portion.
  • Store reconstituted product diluted for infusion at approximately 20°C to 25°C (68°F to 77°F) protected from light for no more than 24 hours. Discard after 24 hours.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide